6 Best Peptides for Fungal Infections

What to Know Before Choosing a Peptide for Fungal Infections

Fungal infections cover a lot of ground. Athlete's foot, nail fungus, and oral thrush sit at one end of the spectrum. Invasive candidiasis and systemic aspergillosis, infections that reach the bloodstream and internal organs, sit at the other. The peptides people discuss and use for these conditions are just as varied, and no single compound covers the whole range.

Every compound in this guide earned its place because people use it or are actively discussing using it for fungal infections. That is the whole test for inclusion. It is not gated on FDA approval, randomized trial data, or commercial availability. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Where the evidence is thin, the entry says so plainly rather than quietly leaving the compound off the list. The entries are numbered by how prominently each compound appears in the research and in documented real-world use, not as a recommendation of one compound over another. The right choice depends on the specific infection, your health situation, and what you build with a personalized plan.

One field-wide reality is worth stating before the entries begin: many of the most-discussed peptides for fungal concerns are not FDA-approved for this use, some are available only through research-chemical channels, and their human evidence ranges from multiple completed randomized trials to a handful of individual user reports. Those differences are real and are described honestly in each entry. Conventional antifungals remain the standard of care for diagnosed infections, and nothing in this guide changes that.

1. Echinocandins: The Only Approved Peptide Antifungals

Echinocandins are lipopeptides, a subclass of peptide-based compounds, and they are the only peptide antifungals in routine clinical use anywhere in the world. Four members of this class carry FDA approval: caspofungin, approved in 2001; micafungin, approved in 2005; anidulafungin, approved in 2006; and rezafungin, the most recently approved member, cleared in 2023. If you have received intravenous treatment for a serious Candida infection in a hospital setting, there is a good chance one of these was involved.

The mechanism is specific and well understood. Echinocandins block an enzyme called beta-1,3-D-glucan synthase, which assembles the fungal cell wall. Disrupting that assembly is roughly like knocking out the scaffolding holding a building together: the wall cannot form, and the cell collapses. Because mammalian cells do not have this enzyme or this type of cell wall, the class has a targeted safety profile compared to older antifungals. Hepatotoxicity is lower than with the azole class, and interactions with cytochrome P450 enzymes, a common mechanism behind drug-drug interactions, are minimal. Nephrotoxicity, the kidney damage that makes amphotericin B so difficult to use, is not a significant concern with echinocandins.

Caspofungin is the only member with FDA approval for invasive aspergillosis, specifically as salvage therapy when patients cannot tolerate or have not responded to first-line treatment. The others are primarily indicated for Candida infections, including candidemia, esophageal candidiasis, and deep-tissue disease. Rezafungin stands out within the class for a once-weekly dosing schedule, a practical improvement over earlier members that require daily infusions.

All four are administered intravenously in clinical settings. They are not self-administered research compounds and are not discussed in biohacking or peptide communities. They appear first in this guide because they are the actual peptide-based antifungals with human clinical trial evidence at scale, and any honest account of the peptide landscape for fungal infections starts here.

2. Novexatin (NP213): For Topical Toenail Fungus

Novexatin, also called NP213, is a synthetic cyclic peptide in Phase IIb clinical trials and currently the most advanced non-echinocandin antifungal peptide with published human data. Its target is onychomycosis, the medical term for fungal nail infection, which primarily affects toenails and is notoriously difficult to treat topically because the nail plate is a significant physical barrier to most compounds.

The mechanism is distinct from both azoles and echinocandins. Novexatin is highly cationic, meaning it carries a strong positive charge, which lets it bind to the negatively charged outer membrane of fungal cells and lyse it directly, punching through and collapsing the cell. This membrane-level action sidesteps the resistance pathways that make azole treatment failures frustratingly common in practice, since resistance to azoles usually involves alterations to the ergosterol synthesis pathway rather than changes to membrane charge.

The clinical evidence is meaningful for a compound at this stage. In one Phase IIb trial, 43 percent of participants achieved culture-negative clearance after a 28-day topical treatment course measured at 180-day follow-up. A second trial returned a culture-negative rate of 56.5 percent under the same protocol. Across both studies, no systemic exposure was detected in plasma after topical application, and the compound was safe and well-tolerated. Topical delivery sidesteps the stability and degradation problems that limit injectable antimicrobial peptides, which is part of why nail fungus is a sensible first target for this class.

Novexatin is not yet approved anywhere and is not available outside of clinical research. People following the peptide and antifungal research space discuss its trial progress rather than personal use protocols. The human data puts it well ahead of most peptides in this guide in terms of direct clinical evidence for a fungal indication.

3. LL-37: For Candida Overgrowth and Mold-Related Illness

LL-37 is a human cathelicidin, a class of host-defense peptides that immune cells including neutrophils, macrophages, and epithelial cells produce naturally as part of the innate immune response. It is a 37-amino acid peptide with broad-spectrum activity covering bacteria, viruses, and fungi. The antifungal dimension, particularly against Candida albicans, is what drives most of the community discussion.

The mechanism LL-37 uses against fungal cells follows the cationic disruption pattern common to many antimicrobial peptides. The peptide carries a positive charge from arginine and lysine residues, which lets it interact electrostatically with the negatively charged outer membrane of fungal cells, disrupting the membrane, causing ion leakage from inside the cell, and eventually killing it. Beyond direct membrane effects, LL-37 also has immunomodulatory properties: it influences how the immune system responds to an infection rather than only attacking the pathogen directly. That dual action is part of why it appears in community discussions about mold illness and systemic Candida rather than straightforward skin infections like athlete's foot.

No human clinical trial has been published specifically studying LL-37 for fungal infections as of 2026. Its antifungal activity against Candida is established in laboratory research, and it is grouped among peptides demonstrating antifungal activity in the scientific literature, but the gap between laboratory activity and clinical approval is substantial. What exists for human use is user-reported experience from community protocols, primarily on forums focused on toxic mold exposure and Candida overgrowth.

The anecdotal reports are specific enough to describe accurately. One widely circulated account describes complete recovery from mold-related illness and nail regrowth after months of stagnation, with a cycling approach of four weeks on followed by one week off. Agitation at higher use levels is the most consistently reported adverse effect. LL-37 is frequently combined in these protocols with VIP (vasoactive intestinal peptide) and BPC-157, and community users often add biofilm-disrupting supplements such as serrapeptase or NAC, reasoning that fungi form biofilms that can limit peptide penetration. One practitioner opinion cited in community discussions described LL-37 as particularly effective for Candida, though this is a clinical perspective rather than controlled trial data.

LL-37 is not FDA-approved for any indication. It is available as a research chemical, and its use in personal health protocols falls into the regulatory gray area surrounding compounds sold for research purposes. Stability is a practical limitation: LL-37 is susceptible to protease degradation in the body, which affects how much active compound reaches the target site after administration.

4. KPV: For Gut and Oral Candida Overgrowth

KPV is a tripeptide made of three amino acids, lysine, proline, and valine, derived from the C-terminal portion of alpha-melanocyte stimulating hormone. Its small size contributes to oral bioavailability that is unusual for peptides, which tend to be broken down in the digestive tract before absorption. Primary research has focused on its anti-inflammatory properties in gut mucosal inflammation and inflammatory bowel disease. The fungal angle is more indirect.

The proposed connection to Candida comes through two routes. The first is immunomodulatory: KPV binds to melanocortin-1 receptors on immune cells and suppresses pro-inflammatory signaling molecules including IL-1 beta, TNF-alpha, and IL-6. In a gut environment where Candida overgrowth is sustaining chronic inflammation, modulating that response may reduce damage to the mucosal lining even if KPV is not directly killing fungal cells. The second route is structural lineage. A related compound called CZEN-002, a synthetic octapeptide derived from the same region of alpha-MSH as KPV, killed 99.7 percent of Candida albicans cells in laboratory studies and is in Phase I and II trials for Candida vaginitis. KPV is not CZEN-002, and the two share a lineage rather than an identity, but the connection gives the compound a scientific thread in the Candida conversation.

No peer-reviewed clinical trials have been published using KPV specifically for Candida or fungal infections as of 2026. The evidence here is experiential rather than clinical. The most detailed user account describes oral use for gut Candida, with nerve pain dropping from roughly an 8 to 9 out of 10 to a 1 to 2 out of 10 within the first two weeks, followed by severe fatigue, dizziness, and complete energy loss around the one-month mark that led to stopping. After discontinuing, the same individual reported no remaining Candida symptoms and an absence of sugar cravings. That is a single anecdotal account, not a controlled observation, and the side effects described, particularly the severe fatigue and energy loss, are the safety signal most consistently flagged in community use.

KPV is not FDA-approved. It is not a scheduled substance, and its regulatory classification varies by country. The fatigue and energy loss that some users report may relate to KPV's immunomodulatory effects altering baseline inflammatory signaling during extended use. The long-term safety profile is not established.

5. VL-2397: For Systemic Aspergillus Infections

VL-2397 is a peptide in Phase I clinical trials targeting invasive aspergillosis, the systemic fungal infection caused by Aspergillus fumigatus that carries high mortality in immunocompromised patients. It is not a compound people self-administer or discuss in community peptide forums. It belongs in this guide because it represents active human clinical development for a serious fungal disease and is part of the honest picture of where peptide antifungal research is heading.

The Phase I study was a first-in-human safety trial. Participants tolerated the compound at doses reaching 1,200 milligrams, and no signs of Aspergillus infection developed in the treated cohort during the observation period. That is a safety milestone rather than an efficacy demonstration: Phase I trials are designed to establish tolerability, and efficacy data for invasive disease will require later-phase studies.

Aspergillus infections are among the most treatment-resistant and deadly fungal diseases in clinical medicine. Existing options including amphotericin B, voriconazole, and isavuconazole each carry meaningful toxicity burdens, and drug resistance in Aspergillus fumigatus is a growing concern. VL-2397 is early in development, and whether it reaches approval is not yet determined. It is included because anyone researching peptide approaches to serious mold-related systemic disease will encounter it in the clinical trial literature, and its aspergillosis indication is distinct from the Candida and nail-fungus focus of the other entries.

6. HXP124: For Topical Nail Fungus Treatment

HXP124 is a topically applied antifungal peptide in Phase I and IIa trials for toenail onychomycosis. It occupies the same research space as Novexatin and the early trial data offers a useful comparison point for anyone tracking the clinical pipeline for nail fungus.

In the Phase I and IIa trial, 37 percent of participants, 15 of 41 total, showed more than a 40 percent reduction in the infected area after 12 weeks of treatment, compared to 18 percent in the vehicle control group. The compound was safe and well-tolerated. Like Novexatin, topical delivery avoids the protease stability and systemic exposure issues that limit injectable antimicrobial peptides.

The trial data is preliminary. The endpoint used, a 40 percent reduction in infection area, is a continuous-measure response threshold rather than a mycological cure endpoint, and Phase I and IIa trials are not powered to establish efficacy with the confidence a Phase III registration trial provides. HXP124 is not available outside clinical research. At this point, Novexatin has more advanced published data for the same indication, but both compounds are being followed by people interested in the peptide pipeline for nail fungal treatment.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for fungal infections?

The echinocandins, caspofungin, micafungin, anidulafungin, and rezafungin, are FDA-approved lipopeptides used in hospital settings for serious Candida infections, and caspofungin carries additional approval for salvage aspergillosis treatment. None of the research peptides covered here, including LL-37 and KPV, are FDA-approved for any indication. Novexatin and HXP124 are in clinical trials but have not been approved anywhere.

Can peptides like LL-37 replace conventional antifungal treatment?

No human clinical trial evidence supports using LL-37 or KPV as a replacement for prescribed antifungal therapy in a diagnosed fungal infection. Community users report using these compounds for Candida overgrowth and mold-related illness, which is a different context from acute diagnosed infections. Conventional antifungals remain the medical standard of care, and anyone with a diagnosed fungal infection should work with a healthcare provider before changing or supplementing a treatment course.

What separates the research peptides from the approved echinocandins?

The echinocandins are rigorously studied intravenous drugs administered in hospitals with well-characterized safety profiles from thousands of patients across controlled trials. Research peptides like LL-37 and KPV have limited or no published human trial data for fungal use and are obtained through research-chemical channels outside standard medical practice. The distance between demonstrating antifungal activity in a laboratory and proving a compound works safely in humans is substantial, and most research peptides are still early in crossing it.

Do people use peptides for common skin fungal infections like athlete's foot or ringworm?

Community peptide forums show very little reported use of research peptides for dermatophyte infections such as athlete's foot, ringworm, or nail fungus managed at home. Users who posted about stubborn recurring skin fungal infections consistently reported resolution with conventional prescription antifungals. The peptide conversation for fungal conditions is concentrated around Candida overgrowth and mold illness rather than typical dermatophyte presentations.

Why do community protocols often combine peptides with biofilm agents?

Fungi including Candida form biofilms, which are structured communities of organisms encased in a protective matrix that can physically block antimicrobial compounds from reaching fungal cells. Community users who report using LL-37 for Candida often add compounds like serrapeptase or NAC alongside it, on the reasoning that disrupting the biofilm first improves peptide access to the underlying cells. This rationale has some basis in research literature on biofilm penetration and antimicrobial peptide efficacy, though the specific combination protocols people use have not been tested in controlled human trials.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for fungal infections in one place.